PDCD1LG2 and neoplasm: Preliminary observations suggest that the main factors explaining differences in PFS under anti-PD-1 therapy are the degree of activation of TLR-4, and the balance between PDL-1, PDL-2, and CTLA-4 activation of the negative immune-blockade, together with the level of infiltration of the tumor by natural killer cells.